Veterinarians

Veterinarians

About Morphogenesis, Inc. and Veterinary Oncology Services, Inc.

Morphogenesis, Inc. and Veterinary Oncology Services, Inc., a subsidiary of Morphogenesis, are developing an array of ImmuneFx cancer vaccines to treat multiple types of cancer in humans, dogs, cats and horses. The ImmuneFx vaccines include whole cell autologous, whole cell allogeneic and direct DNA vaccines. Each form of delivery has its own advantages.

Veterinary by listening to a catVeterinary Oncology Services offer the whole cell autologous form of ImmuneFx (IFx-VET), which is manufactured from a patient’s own tumor cells at the Veterinary Oncology Services facility. This personalized form of therapy is available through veterinarians across the US, having received authorization from the Center for Veterinary Biologics to provide this service. To date, thousands of doses of personalized IFx-VET have been administered to dogs, cats and horses, and no side effects have been observed, so no supportive therapy is needed. This not only decreases the cost to pet parents, it provides great comfort knowing that the therapy has no adverse reactions.

Learn More About Treatment

 

How IFx-VET can Help Vets

Young woman with a dog at veterinarianIFx-VET is a therapeutic cancer vaccine, which is a type of immunotherapy. Immunotherapies are treatments that take advantage to the body’s innate ability to fight disease. Immunotherapies include cancer vaccines, checkpoint inhibitors and chimeric T cell receptors (CAR-T). While dendritic cell cancer vaccines and CAR-T therapies are complicated to engineer and costly to produce, making them impractical for development in veterinary applications, some types of cancer vaccines can be adapted to the treatment of companion animals.

IFx-VET is one of the more promising approaches to treating cancers in companion animals. Unlike single indication DNA/peptide/protein cancer vaccines, IFx-VET does not rely on an immune response to a single tumor-related protein to fight a constantly evolving, heterogeneous population of tumor cells. Because the vaccine protein is expressed alongside all the abnormal proteins, a strong immune response is primed and educated to attack cells throughout the body bearing any of these abnormal proteins.